Key Findings
In a strategic move to accelerate the commercialization of cell and gene therapies (CGT), CCRM and its Contract Development and Manufacturing Organization (CDMO) subsidiary, OmniaBio Inc., announced a partnership with Avectas Limited. This collaboration aims to evaluate and potentially integrate Avectas’s advanced technology to establish an automated, integrated, and scalable cell therapy manufacturing platform.
Technical / Clinical Details
- Evaluation of Avectas Technology: Central to the partnership is assessing how Avectas’s platform can complement CCRM’s growing global network and OmniaBio’s initiatives to implement standardized, automated manufacturing workflows. Avectas’s technology holds potential for improving the efficiency of cell introduction processes and cell viability.
- OmniaBio’s Expertise: OmniaBio possesses deep expertise in the clinical and commercial manufacturing of immune cell-based therapies, induced pluripotent stem cell (iPSC) therapies, CAR-T cell therapies, and lentiviral vectors. This broad specialization indicates flexible manufacturing capabilities to accommodate various cell therapy modalities.
- Driving Automation and Standardization: Cell therapy manufacturing is challenged by its complexity, reliance on manual processes, and high costs. CCRM and OmniaBio aim to overcome these issues by driving automation and standardization, thereby improving manufacturing consistency, reproducibility, and efficiency. The partnership with Avectas marks a critical step towards achieving this goal.
- Global Network and Ecosystem: CCRM has built a robust network with academic institutions, industry players, and regulatory bodies worldwide, serving as a central hub for supporting R&D and commercialization in the cell and gene therapy sector. This collaboration further strengthens this ecosystem, offering opportunities to deploy innovative manufacturing technologies globally.
Background & Context
Cell and gene therapies hold immense promise as groundbreaking treatments for many severe diseases. However, their commercialization faces a significant challenge: establishing scalable and cost-effective manufacturing processes. Particularly, cell quality, homogeneity, and manufacturing lead times are key to product market entry and patient access. CCRM and OmniaBio’s partnership with Avectas reflects an industry-wide effort to address these challenges and build the next generation of cell therapy manufacturing.
Strategic Significance & Outlook
This partnership will enable OmniaBio to evaluate Avectas’s technology and explore its potential integration into manufacturing workflows, further advancing cell therapy manufacturing automation and efficiency. If successful, it could lead to reduced manufacturing costs for cell therapy products, improved supply capacity, and ultimately allow more patients to benefit from these innovative therapies. Strategic alliances of this nature are indispensable for the sustained growth and commercialization of the cell and gene therapy sector and are expected to accelerate innovation across the industry.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments